Active-ingredient Dossier
Irinotecan Hydrochloride Trihydrate
Active-ingredient Dossier for Irinotecan Hydrochloride Trihydrate (topoisomerase inhibitor). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: IRINOTECAN
- Brand: ONIVYDE
- Brand: IRINOTECAN
- Brand: IRINOTECAN
- Brand: MEDITAB
- Brand: CAMPTOSAR
- Therapeutic area: Oncology
What is
Irinotecan Hydrochloride Trihydrate Irinotecan Hydrochloride Trihydrate is a topoisomerase inhibitor.
Australian brands containing
Irinotecan Hydrochloride Trihydrate The following brands containing this ingredient are registered on the ARTG: — IRINOTECAN — ONIVYDE — CAMPTOSAR — MEDITAB — EUG-IRINOTECAN — GENRX
Therapeutic areas
Irinotecan Hydrochloride Trihydrate is registered in oncology (11 brands) and complementary medicine (1 brand).
Sponsor landscape
The ingredient is marketed by nine sponsors, including Baxter Healthcare, Eugia Pharma, Pfizer, Pfizer (Perth), KSJ Pharmatech, and Accord Healthcare.
PBS and regulatory activity
One brand containing this ingredient has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was recorded on 1 November 2024, and two brands have PBAC outcomes on record.